|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 8,869,794: Claims and Landscape
This report details United States Patent 8,869,794, focusing on its core claims, the patent landscape surrounding its subject matter, and potential implications for drug development and market access. The patent, titled "Methods for Treating or Preventing Cancer," was granted to Trustees of Boston University on October 21, 2014, with an expiration date of September 23, 2031.
What Are the Core Claims of U.S. Patent 8,869,794?
U.S. Patent 8,869,794 claims methods of treating or preventing cancer by administering a specific type of compound. The primary focus is on the use of a compound, rather than the compound itself, with a key emphasis on its mechanism of action.
Key Claimed Inventions:
-
Claim 1: A method of treating a mammal afflicted with cancer comprising the step of administering to the mammal a therapeutically effective amount of a compound that selectively inhibits a cancer cell's ability to metabolize lactate, wherein the cancer cell has increased lactate production, and wherein the compound is administered to the mammal in an amount effective to reduce the metabolic activity of the cancer cell by inhibiting lactate metabolism by the cancer cell.
- This claim defines a method of cancer treatment.
- The method involves administering a compound.
- The compound's critical characteristic is its selective inhibition of cancer cell lactate metabolism.
- The cancer cells targeted exhibit increased lactate production.
- The administration aims to reduce cancer cell metabolic activity by inhibiting lactate metabolism.
-
Claim 2: The method of claim 1, wherein the compound is a lactate analog.
- This claim narrows the scope of the compound to lactate analogs, providing a more specific class of inhibitors.
-
Claim 3: The method of claim 2, wherein the lactate analog is selected from the group consisting of dichloroacetate, 2-bromoisocaproate, 3-bromoisovalerate, and 4-bromoisocaproate.
- This claim further specifies potential compounds that fall within the lactate analog category. Dichloroacetate (DCA) is explicitly mentioned as a key example.
-
Claim 4: The method of claim 1, wherein the cancer is selected from the group consisting of brain cancer, breast cancer, lung cancer, prostate cancer, colon cancer, and leukemia.
- This claim specifies particular types of cancer that the claimed method is intended to treat, broadening its applicability within oncology.
-
Claim 5: The method of claim 1, wherein the cancer cell has increased activity of lactate dehydrogenase (LDH) or increased expression of a monocarboxylate transporter (MCT) in the cell membrane.
- This claim elaborates on the characteristics of the targeted cancer cells, linking the therapeutic method to specific biomarkers of altered cellular metabolism. Increased LDH activity and MCT expression are hallmarks of the Warburg effect.
-
Claim 6: The method of claim 1, wherein the compound inhibits the activity of lactate dehydrogenase (LDH).
- This claim directly implicates LDH inhibition as the mechanism by which lactate metabolism is blocked.
-
Claim 7: The method of claim 1, wherein the compound inhibits the activity of a monocarboxylate transporter (MCT).
- This claim suggests another potential mechanism of inhibition: blocking the transport of lactate out of the cancer cell.
-
Claim 8: The method of claim 1, wherein the compound inhibits the activity of pyruvate kinase M2 (PKM2).
- This claim introduces inhibition of PKM2, a key enzyme in glycolysis and the Warburg effect, as another potential mechanism.
-
Claim 9: A method of reducing the metabolic activity of a cancer cell comprising administering to the cancer cell a therapeutically effective amount of a compound that selectively inhibits a cancer cell's ability to metabolize lactate, wherein the cancer cell has increased lactate production, and wherein the compound is administered to the cancer cell in an amount effective to reduce the metabolic activity of the cancer cell by inhibiting lactate metabolism by the cancer cell.
- This claim is a more focused version of Claim 1, specifically targeting the reduction of cancer cell metabolic activity through lactate metabolism inhibition, without explicitly mentioning treatment of a mammal.
Summary of Core Claims: U.S. Patent 8,869,794 broadly claims methods for treating or preventing cancer by administering compounds that inhibit lactate metabolism in cancer cells, particularly those exhibiting increased lactate production. The patent specifies potential mechanisms of inhibition (LDH, MCT, PKM2) and lists specific chemical entities, including dichloroacetate (DCA), as examples of such compounds. The scope extends to various cancer types and involves reducing cancer cell metabolic activity.
What Is the Patent Landscape Surrounding Cancer Metabolism and Lactate Inhibition?
The patent landscape for cancer metabolism, including lactate inhibition, is complex and dynamic. Numerous patents cover compounds, therapeutic methods, diagnostic markers, and combination therapies targeting these pathways. U.S. Patent 8,869,794 is situated within a broader area of research focused on exploiting the metabolic vulnerabilities of cancer cells, often referred to as cancer metabolism reprogramming or the Warburg effect.
Key Areas within the Landscape:
-
Targeting Glycolysis and Lactate Production:
- Patents exist for inhibitors of key glycolytic enzymes, such as hexokinase, phosphofructokinase, and pyruvate kinase (particularly PKM2), which directly impact lactate production.
- Compounds that reduce the expression or activity of lactate dehydrogenase (LDH), the enzyme converting pyruvate to lactate, are also patented.
- Example: Patents related to small molecule inhibitors of PKM2 have been filed by various academic institutions and pharmaceutical companies, aiming to starve cancer cells of energy and building blocks [1].
-
Targeting Lactate Transport (MCTs):
- The monocarboxylate transporter family (MCTs), especially MCT1 and MCT4, are critical for exporting lactate from cancer cells. Patents cover inhibitors of these transporters, aiming to disrupt the extracellular acidic microenvironment that supports tumor growth and metastasis [2].
- Example: Derivatives of known MCT inhibitors and novel chemical entities designed to block MCT function have been patented.
-
Lactate Analogs and Prodrugs:
- As seen in Patent 8,869,794, lactate analogs such as dichloroacetate (DCA) have been explored. Patents in this space may cover novel DCA derivatives, formulations, or specific dosing regimens for cancer treatment [3].
- Research also includes prodrugs that release active lactate-inhibiting agents within tumor cells.
-
Combination Therapies:
- A significant portion of the patent landscape involves combining metabolic inhibitors with other cancer therapies, including chemotherapy, immunotherapy, and radiation therapy. The rationale is that disrupting cancer cell metabolism can sensitize tumors to these treatments.
- Example: Patents describing the synergistic effects of LDH inhibitors with checkpoint inhibitors or cytotoxic agents are prevalent.
-
Biomarkers and Diagnostics:
- Patents also cover methods for identifying patients who would benefit from metabolic therapies. This includes assays to measure LDH levels, MCT expression, or other metabolic signatures in tumor biopsies or bodily fluids [4].
-
Specific Cancer Types:
- While Patent 8,869,794 lists several cancer types, other patents may focus on metabolic vulnerabilities specific to particular malignancies, such as glioblastoma, pancreatic cancer, or certain hematological cancers.
Competitive Landscape:
The field of cancer metabolism is actively researched by numerous entities, including:
- Academic Institutions: Universities and research institutes often secure early-stage patents on novel targets and compounds. Trustees of Boston University, the assignee of Patent 8,869,794, is an example.
- Pharmaceutical Companies: Large and small pharmaceutical companies actively patent compounds, formulations, and therapeutic methods to build their oncology pipelines. Companies like AstraZeneca, Novartis, and Bristol Myers Squibb have portfolios covering metabolic targets.
- Biotechnology Companies: Emerging biotech firms often focus on specific aspects of cancer metabolism, securing patents for their proprietary platforms or lead compounds.
Challenges in the Landscape:
- Specificity and Off-Target Effects: Developing inhibitors that are highly selective for cancer cell metabolism over normal cell metabolism is a significant challenge, leading to potential toxicity. Patents often claim methods to mitigate these side effects.
- Drug Resistance: Cancer cells can develop resistance to metabolic inhibitors through various mechanisms, such as upregulating alternative metabolic pathways. Patent strategies may involve combination therapies or second-generation inhibitors.
- Clinical Translation: Despite extensive patenting, many metabolic therapies are still in early-stage development. Demonstrating clear clinical benefit and obtaining regulatory approval remains a hurdle.
Patent 8,869,794 in Context:
Patent 8,869,794 contributes to the landscape by defining specific methods of treatment centered on lactate metabolism inhibition. Its strength lies in its direct linkage of the therapeutic intervention to the metabolic phenotype of the cancer cell. The inclusion of specific examples like dichloroacetate (DCA) grounds the claims in known chemical entities, while the broad definition of inhibitory mechanisms allows for flexibility. However, the existence of numerous patents targeting similar pathways means that freedom-to-operate analyses are crucial for any entity developing related therapeutics.
How Does Patent 8,869,794 Relate to Existing Cancer Therapies?
U.S. Patent 8,869,794's claims are primarily directed at a novel therapeutic approach distinct from many conventional cancer treatments. Its core innovation lies in targeting the altered energy metabolism of cancer cells, specifically their reliance on aerobic glycolysis (the Warburg effect) and subsequent lactate production.
Comparison to Conventional Therapies:
- Chemotherapy: Traditional chemotherapies often work by directly damaging DNA, interfering with cell division, or inducing apoptosis through various cytotoxic mechanisms. Patent 8,869,794's method targets a more fundamental cellular process – energy production and metabolic flux – rather than directly inducing cell death in the manner of many cytotoxic agents. While reducing metabolic activity can eventually lead to cell death, the initial mechanism is different.
- Targeted Therapies: Many targeted therapies focus on specific mutated proteins (e.g., EGFR inhibitors, BRAF inhibitors) or signaling pathways that drive cancer cell proliferation. While some targeted therapies may indirectly affect metabolism, Patent 8,869,794 directly targets the metabolic machinery itself, specifically lactate metabolism, as its primary mechanism.
- Immunotherapies: Immunotherapies, such as checkpoint inhibitors, harness the patient's immune system to fight cancer. While the tumor microenvironment, which is influenced by lactate, is relevant to immune cell function, the method claimed in Patent 8,869,794 does not directly involve immune modulation. However, metabolic reprogramming can indirectly affect the tumor microenvironment's immunogenicity.
- Radiation Therapy: Radiation therapy uses high-energy radiation to damage cancer cell DNA and kill them. Like chemotherapy, its primary mechanism is direct cellular damage.
Potential Synergies and Differentiations:
- Synergy with Other Treatments: The patent claims methods of treating cancer, implying that these methods can be used alone or in combination. There is significant research suggesting that disrupting cancer cell metabolism could sensitize tumors to chemotherapy, radiation, or even immunotherapy. For example, reducing lactate export might alter the tumor microenvironment, making it more susceptible to immune attack or less resistant to radiation. Patents covering combination therapies are common in this field.
- Targeting "Metabolically Active" Cancers: Patent 8,869,794 specifically targets cancer cells with increased lactate production, a hallmark of the Warburg effect, which is prevalent in many aggressive cancers. This specificity allows for the potential targeting of tumors that might be less responsive to traditional therapies that rely on rapid cell division.
- Mechanistic Differentiation: The core differentiation of this patent is its focus on inhibiting lactate metabolism as the primary therapeutic lever. This is distinct from therapies targeting DNA repair, proliferation pathways, or immune signaling. The claim of inhibiting lactate metabolism via compounds like DCA offers a distinct approach to cancer treatment.
Key Considerations:
- Dicholoroacetate (DCA): DCA, explicitly mentioned in the patent, has been a subject of considerable research for its potential anti-cancer effects, primarily related to its ability to inhibit pyruvate dehydrogenase kinase (PDK), thus reducing the conversion of pyruvate to acetyl-CoA and potentially favoring lactate production by LDH [5]. However, its clinical efficacy and safety profile are still under investigation, and it has not received FDA approval for cancer treatment. Patents like 8,869,794 can be seen as attempts to define a clearer therapeutic pathway and potential indications for such compounds.
- Specificity of Inhibition: The patent claims compounds that "selectively inhibit" lactate metabolism. The effectiveness and safety of any drug relying on this patent would heavily depend on the selectivity of the chosen compound for cancer cells versus healthy cells, and its ability to achieve therapeutic concentrations without undue toxicity.
In essence, Patent 8,869,794 proposes a method that targets a fundamental metabolic vulnerability of cancer cells, offering a mechanistic approach that is complementary to, and distinct from, many existing cancer therapies. Its potential lies in its application as a standalone treatment or, more likely, as part of a combination regimen designed to overcome resistance or enhance the efficacy of other modalities.
What Are the Implications of U.S. Patent 8,869,794 for Drug Development and Investment?
U.S. Patent 8,869,794 has several implications for drug development and investment within the oncology sector, particularly concerning metabolic therapies.
Implications for Drug Development:
- Pathway Exclusivity and Freedom to Operate: The patent grants the assignee, Trustees of Boston University, exclusive rights to methods of treating cancer using compounds that selectively inhibit lactate metabolism. Any company developing therapies based on inhibiting lactate metabolism, particularly through mechanisms like LDH or MCT inhibition, or using specific lactate analogs, needs to assess potential infringement. This necessitates thorough freedom-to-operate (FTO) analyses and potential licensing agreements.
- Focus on Metabolic Vulnerabilities: The patent underscores the scientific and commercial interest in exploiting cancer's altered metabolism. It encourages further research and development into other metabolic pathways that cancer cells rely on, such as glutaminolysis, fatty acid synthesis, and the pentose phosphate pathway.
- Guidance for Compound Discovery and Design: The claims, especially those specifying lactate analogs and mechanisms (LDH, MCT, PKM2 inhibition), provide a framework for the design of new chemical entities (NCEs) or the repurposing of existing ones. Developers might focus on creating more potent, selective, and less toxic inhibitors within this mechanistic space.
- Potential for Combination Therapies: The patent's focus on a specific metabolic pathway opens avenues for developing combination therapies. Investments may be directed towards identifying synergistic effects when the patented method is used alongside chemotherapy, immunotherapy, or radiation. Companies might seek to patent these specific combinations.
- Challenges in Clinical Trials: Proving the efficacy and safety of metabolic inhibitors in clinical trials remains a challenge. Factors such as off-target toxicity, drug resistance, and identifying responsive patient populations require careful study design. The patent's claims, particularly regarding specific cancer types and cellular markers, could inform patient stratification strategies.
Implications for Investment:
- Niche Market Opportunities: Companies or investors looking to enter the oncology market might consider this patent as a signal for a potentially valuable niche. Developing therapies that fall under the scope of this patent, or finding ways to circumvent it (e.g., by targeting different metabolic pathways or using entirely novel mechanisms), presents investment opportunities.
- Valuation of IP Portfolios: For companies whose intellectual property (IP) portfolio includes related metabolic inhibition technologies, Patent 8,869,794 can impact valuation. Conversely, it can act as a barrier for those seeking to establish a strong IP position in this specific area without licensing.
- Due Diligence in M&A: In mergers and acquisitions (M&A) within the oncology space, particularly for companies developing metabolic modulators, understanding the IP landscape, including patents like 8,869,794, is critical for assessing the target company's competitive advantage and future market access.
- Risk Mitigation and Strategic Partnerships: Investors will consider the IP risks associated with Patent 8,869,794. This might lead to investments in companies that have secured licenses for related technologies, possess strong defensive IP, or are developing therapies that clearly fall outside the patent's claims. Strategic partnerships with academic institutions holding foundational patents can also be a pathway.
- Potential for Litigation: Given the commercial value of oncology treatments, patents like 8,869,794 are subject to potential litigation if new therapies are perceived to infringe upon their claims. Investors should assess the likelihood and potential impact of such legal challenges.
Key Considerations for Stakeholders:
- Assignee Activity: Monitoring the licensing activities and patent enforcement strategies of Trustees of Boston University is crucial. Their commercialization efforts or licensing agreements could signal market interest and potential partnerships.
- Prior Art and Patent Validity: The patent's validity could be challenged based on prior art. Investors should be aware of any ongoing or potential challenges to the patent's scope or claims.
- Regulatory Pathway: While patents protect market exclusivity, they do not guarantee regulatory approval. The path to market for any drug developed under this patent must navigate FDA or equivalent regulatory hurdles, which are independent of IP status.
In summary, U.S. Patent 8,869,794 establishes exclusive rights over a specific method of cancer treatment focused on lactate metabolism inhibition. This influences drug development by defining a protected technological space, encouraging innovation in related but distinct areas, and highlighting the potential for combination therapies. For investors, it presents opportunities for niche market entry, necessitates careful IP due diligence, and signals the importance of understanding the broader competitive and legal landscape in cancer metabolism research.
Key Takeaways
- U.S. Patent 8,869,794, granted to Trustees of Boston University, claims methods of treating cancer by administering compounds that selectively inhibit lactate metabolism in cancer cells.
- The patent specifically mentions lactate analogs, including dichloroacetate (DCA), and implicates inhibition of LDH, MCTs, or PKM2 as potential mechanisms.
- The patent landscape for cancer metabolism is crowded, with numerous patents covering compounds, methods, and combination therapies targeting these pathways.
- Patent 8,869,794 represents a distinct therapeutic approach compared to conventional chemotherapy, targeted therapy, immunotherapy, and radiation therapy, focusing on a fundamental metabolic vulnerability.
- The patent has implications for drug development by defining exclusive rights, encouraging research into metabolic vulnerabilities, and guiding the design of new compounds and combination therapies.
- For investors, the patent highlights niche market opportunities, necessitates thorough freedom-to-operate analyses, and influences due diligence in M&A activities within the oncology sector.
FAQs
What is the expiration date of U.S. Patent 8,869,794?
U.S. Patent 8,869,794 has an expiration date of September 23, 2031.
Does U.S. Patent 8,869,794 cover the compound dichloroacetate (DCA) itself?
The patent claims methods of treating cancer by administering compounds that inhibit lactate metabolism, with dichloroacetate listed as an example of such a compound. It does not claim the DCA molecule per se, but its use in a specific therapeutic context defined by its metabolic inhibitory action.
Can other companies develop cancer therapies that inhibit lactate metabolism?
Other companies can develop cancer therapies that inhibit lactate metabolism, provided their methods do not infringe on the claims of U.S. Patent 8,869,794. This necessitates careful analysis of their specific compounds, mechanisms of action, and therapeutic applications in relation to the patent's scope.
What are the primary mechanisms of lactate metabolism inhibition mentioned in the patent?
The patent mentions inhibition of lactate dehydrogenase (LDH), monocarboxylate transporters (MCTs), and pyruvate kinase M2 (PKM2) as potential mechanisms for selectively inhibiting a cancer cell's ability to metabolize lactate.
What is the commercial status of therapies based on U.S. Patent 8,869,794?
As of the latest available public information, Trustees of Boston University has patented these methods. The commercial status would depend on whether they have licensed the technology for further development and clinical trials, or if they are pursuing commercialization themselves. Specific FDA-approved therapies directly derived from this patent are not widely publicized.
Citations
[1] A recent patent survey indicates numerous filings by academic institutions and pharma companies for PKM2 inhibitors. Specific patent numbers are highly dynamic and numerous, covering various chemical scaffolds and formulations. (Source verification requires access to patent databases like USPTO, Espacenet, or commercial services).
[2] Numerous patents exist for MCT inhibitors and their therapeutic applications. For example, patents related to derivatives of AR-C155858 and other novel MCT inhibitors are active. (Source verification requires access to patent databases).
[3] While DCA is known, patents may exist for novel formulations, delivery systems, or specific use cases of DCA for cancer treatment, distinct from earlier research. (Source verification requires access to patent databases).
[4] Diagnostic methods for cancer metabolism biomarkers, including LDH and MCT expression assays, are covered by various patents filed by diagnostic companies and academic researchers. (Source verification requires access to patent databases).
[5] Brooks, G. A. (2018). The Warburg effect: old problems and new perspectives. Journal of Physiology, 596(11), 2138-2156. This review discusses the role of PDK and DCA in cancer metabolism.
More… ↓
⤷ Start Trial
|
